Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

Neelam Sinha, Sanju Sinha, Kuoyuan Cheng, Sanna Madan, Ayelet Erez, Bríd M. Ryan, Alejandro A. Schäffer, Kenneth Aldape, Eytan Ruppin*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)1147-1150
Number of pages4
JournalJCO Precision Oncology
StatePublished - 2021
Externally publishedYes

Cite this